Atreca, Inc. (BCEL) Stock

About Atreca, Inc.

Atreca, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing antibody-based immunotherapies for various solid tumor indications. Its lead investigational therapeutic, ATRC-101, is a monoclonal antibody distinguished by its novel mechanism of action and a unique target, both identified through the company's proprietary discovery platform. In in vitro studies, ATRC-101 has demonstrated reactivity with a significant proportion of human ovarian, non-small cell lung, colorectal, and breast cancer samples sourced from diverse patient populations. The pipeline also includes APN-122597, a receptor tyrosine kinase engineered to specifically target tumor tissues, and ATRC-501/MAM01, an agent aimed at the circumsporozoite protein of Plasmodium falciparum for malaria treatment. Beyond its internal programs, Atreca maintains strategic alliances, including a collaboration and licensing agreement with Xencor, Inc. for the research, development, and commercialization of innovative CD3 bispecific antibodies in oncology. Additionally, it holds a licensing agreement with the Bill & Melinda Gates Medical Research Institute for the advancement and commercialization of MAM01/ATRC-501, specifically for malaria prevention. Founded in 2010, Atreca, Inc. is headquartered in San Carlos, California.

Atreca, Inc. is headquartered in US.

Atreca, Inc. (BCEL) stock trades at $0.09 with a market capitalization of $3.57M. The stock is valued at a price-to-earnings (P/E) ratio of -0.04, price-to-book of 0.04, price-to-sales of 4.63. Over the past 52 weeks the stock has ranged between $0.05 and $1.20, and currently trades 92.5% below its 52-week high.

On profitability, Atreca, Inc. generates a return on equity (ROE) of -83.28%, return on capital employed of -70.29%, an operating margin of -9800.00%, a net profit margin of -9700.00%.

Official website: www.atreca.com